Co announced the first poster, Emergent scientists described the efficacy of ES414 to prevent growth of human prostate cancer cells in vivo that express the PSMA protein on their surface: "Anti-PSMA x anti-CD3 ADAPTIR molecule inhibits tumor growth in vivo" Treatment with ES414 showed statistically significant inhibition of subcutaneous tumor outgrowth in the presence of human T cells in two independent mouse xenograft models of prostate cancer (C4-2B, MDA-PCa-2b). In both models, all treatment groups also showed a statistically significant decrease in serum PSA compared to negative controls.
Co announced The second poster described initial PK and tolerability: "Pharmacokinetic evaluation and tolerability assessment of anti-PSMA x anti-CD3 ADAPTIR molecule" These non-clinical studies showed that ES414 is pharmacologically active, has an extended serum half-life compared to antibody fragments, is well tolerated at levels well above the expected human dose, and possesses suitable characteristics for further in vivo toxicology studies.
Recent EBS News
- Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/22/2024 12:05:00 PM
- Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis • GlobeNewswire Inc. • 03/28/2024 12:15:03 PM
- Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility • GlobeNewswire Inc. • 03/25/2024 12:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 09:21:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:31:51 AM
- Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results • GlobeNewswire Inc. • 03/06/2024 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:15:47 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:43:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:42:33 PM
- Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 01:30:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 01:28:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:25:51 PM
- Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 12:41:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:40:06 PM
- Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 • GlobeNewswire Inc. • 01/09/2024 12:30:00 PM
- Wall Street Highlights: Apple Appeals Watch Ban, Tesla to Launch Updated Model Y, and More • IH Market News • 12/27/2023 11:08:22 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/11/2023 10:22:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/11/2023 12:24:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 12:15:22 PM
- Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) • GlobeNewswire Inc. • 11/28/2023 11:59:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM